234 related articles for article (PubMed ID: 27771231)
1. Evaluating strategies to improve HIV care outcomes in Kenya: a modelling study.
Olney JJ; Braitstein P; Eaton JW; Sang E; Nyambura M; Kimaiyo S; McRobie E; Hogan JW; Hallett TB
Lancet HIV; 2016 Dec; 3(12):e592-e600. PubMed ID: 27771231
[TBL] [Abstract][Full Text] [Related]
2. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
Lancet Glob Health; 2014 Jan; 2(1):e23-34. PubMed ID: 25104632
[TBL] [Abstract][Full Text] [Related]
3. Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial.
Thomas R; Probert WJM; Sauter R; Mwenge L; Singh S; Kanema S; Vanqa N; Harper A; Burger R; Cori A; Pickles M; Bell-Mandla N; Yang B; Bwalya J; Phiri M; Shanaube K; Floyd S; Donnell D; Bock P; Ayles H; Fidler S; Hayes RJ; Fraser C; Hauck K;
Lancet Glob Health; 2021 May; 9(5):e668-e680. PubMed ID: 33721566
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.
Smith JA; Sharma M; Levin C; Baeten JM; van Rooyen H; Celum C; Hallett TB; Barnabas RV
Lancet HIV; 2015 Apr; 2(4):e159-68. PubMed ID: 25844394
[TBL] [Abstract][Full Text] [Related]
5. Optimal timing of HIV home-based counselling and testing rounds in Western Kenya.
Olney JJ; Eaton JW; Braitstein P; Hogan JW; Hallett TB
J Int AIDS Soc; 2018 Jun; 21(6):e25142. PubMed ID: 29883052
[TBL] [Abstract][Full Text] [Related]
6. Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis.
Ying R; Sharma M; Celum C; Baeten JM; van Rooyen H; Hughes JP; Garnett G; Barnabas RV
Lancet HIV; 2016 Jun; 3(6):e275-82. PubMed ID: 27240790
[TBL] [Abstract][Full Text] [Related]
7. Universal test, treat, and keep: improving ART retention is key in cost-effective HIV control in Uganda.
McCreesh N; Andrianakis I; Nsubuga RN; Strong M; Vernon I; McKinley TJ; Oakley JE; Goldstein M; Hayes R; White RG
BMC Infect Dis; 2017 May; 17(1):322. PubMed ID: 28468605
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.
Keebler D; Revill P; Braithwaite S; Phillips A; Blaser N; Borquez A; Cambiano V; Ciaranello A; Estill J; Gray R; Hill A; Keiser O; Kessler J; Menzies NA; Nucifora KA; Vizcaya LS; Walker S; Welte A; Easterbrook P; Doherty M; Hirnschall G; Hallett TB
Lancet Glob Health; 2014 Jan; 2(1):e35-43. PubMed ID: 25104633
[TBL] [Abstract][Full Text] [Related]
9. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.
Smith J; Bansi-Matharu L; Cambiano V; Dimitrov D; Bershteyn A; van de Vijver D; Kripke K; Revill P; Boily MC; Meyer-Rath G; Taramusi I; Lundgren JD; van Oosterhout JJ; Kuritzkes D; Schaefer R; Siedner MJ; Schapiro J; Delany-Moretlwe S; Landovitz RJ; Flexner C; Jordan M; Venter F; Radebe M; Ripin D; Jenkins S; Resar D; Amole C; Shahmanesh M; Gupta RK; Raizes E; Johnson C; Inzaule S; Shafer R; Warren M; Stansfield S; Paredes R; Phillips AN;
Lancet HIV; 2023 Apr; 10(4):e254-e265. PubMed ID: 36642087
[TBL] [Abstract][Full Text] [Related]
10. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
[TBL] [Abstract][Full Text] [Related]
11. Voluntary Community Human Immunodeficiency Virus Testing, Linkage, and Retention in Care Interventions in Kenya: Modeling the Clinical Impact and Cost-effectiveness.
Luong Nguyen LB; Yazdanpanah Y; Maman D; Wanjala S; Vandenbulcke A; Price J; Parker RA; Hennequin W; Mendiharat P; Freedberg KA
Clin Infect Dis; 2018 Aug; 67(5):719-726. PubMed ID: 29746619
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study.
Sharma M; Mudimu E; Simeon K; Bershteyn A; Dorward J; Violette LR; Akullian A; Abdool Karim SS; Celum C; Garrett N; Drain PK
Lancet HIV; 2021 Apr; 8(4):e216-e224. PubMed ID: 33347810
[TBL] [Abstract][Full Text] [Related]
13. Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models.
Bershteyn A; Jamieson L; Kim HY; Platais I; Milali MP; Mudimu E; Ten Brink D; Martin-Hughes R; Kelly SL; Phillips AN; Bansi-Matharu L; Cambiano V; Revill P; Meyer-Rath G; Nichols BE
Lancet Glob Health; 2022 Sep; 10(9):e1298-e1306. PubMed ID: 35961353
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania.
Sweat M; Gregorich S; Sangiwa G; Furlonge C; Balmer D; Kamenga C; Grinstead O; Coates T
Lancet; 2000 Jul; 356(9224):113-21. PubMed ID: 10963247
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.
Nosyk B; Min JE; Lima VD; Hogg RS; Montaner JS;
Lancet HIV; 2015 Sep; 2(9):e393-400. PubMed ID: 26423553
[TBL] [Abstract][Full Text] [Related]
16. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050.
Granich R; Kahn JG; Bennett R; Holmes CB; Garg N; Serenata C; Sabin ML; Makhlouf-Obermeyer C; De Filippo Mack C; Williams P; Jones L; Smyth C; Kutch KA; Ying-Ru L; Vitoria M; Souteyrand Y; Crowley S; Korenromp EL; Williams BG
PLoS One; 2012; 7(2):e30216. PubMed ID: 22348000
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of 'test and treat' policy for antiretroviral therapy among heterosexual HIV population in India.
Singh M; Sharma A; Bahuguna P; Jyani G; Prinja S
Indian J Med Res; 2022 Jun; 156(6):705-714. PubMed ID: 37056069
[TBL] [Abstract][Full Text] [Related]
18. Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence.
Currie CS; Floyd K; Williams BG; Dye C
BMC Public Health; 2005 Dec; 5():130. PubMed ID: 16343345
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.
Marseille E; Kahn JG; Mmiro F; Guay L; Musoke P; Fowler MG; Jackson JB
Lancet; 1999 Sep; 354(9181):803-9. PubMed ID: 10485721
[TBL] [Abstract][Full Text] [Related]
20. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
